Investor mix
7 investors on record; lead investors include Life Sciences Partners; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 57% |
| Private equity | 2 | 29% |
| Bank & private debt | 1 | 14% |
Antibody-based protein therapies primarily for cancer
7 investors on record; lead investors include Life Sciences Partners; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 57% |
| Private equity | 2 | 29% |
| Bank & private debt | 1 | 14% |